CA
NZ
UK
AU
IND
US
Zenas BioPharma (NASDAQ:ZBIO) is rebounding in Thursday's session, trading near $28.73 and recovering part of a roughly 9.7% decline over the past week. The Waltham, Massachusetts-based clinical-stage company develops immunology therapies for autoimmune disease, led by obexelimab, a bifunctional antibody targeting CD19 and FcγRIIb, …
Quantum-Si (NASDAQ:QSI) released interim development results on September 28, 2026 and presented them at the World HUPO Congress in Singapore on September 29. Chief executive Jeff Hawkins called Proteus a fundamentally superior platform rather than a bigger Platinum Pro and said the system is …
Apnimed (NASDAQ:APMD) priced its IPO at USD 16 on July 30, 2026 and began trading on theNasdaqGlobal Select Market on July 31. Its only clinical product is Oxnimbi, a once-daily oral pill combining aroxybutynin, an antimuscarinic, with atomoxetine, a norepinephrine reuptake inhibitor, intended to …
Inogen (NASDAQ:INGN) agreed to sell its U.S. oxygen rental division to Rotech Healthcare, a national home respiratory provider, under an asset purchase agreement. Rotech will acquire specified rentalAssetsfor estimated cash of up to USD 25 million, and the companies signed a separate long-termSupplyagreement under …
Autonomix Medical, Inc. (NASDAQ:AMIX) develops a catheter with a microchip sensing array that detects nerve signals from inside a blood vessel, with the aim of finding and treating overactive nerves that cause pain or high blood pressure. All of its candidates are Class II …
DataMeds AI, Inc. (NASDAQ:MEDS) had been in litigation with the sellers of Wellgistics, LLC, which it bought under an agreement dated May 11, 2023. The company had sued in Florida state court, and the sellers had sued in the Delaware Court of Chancery over …
Jaguar Health, Inc. (NASDAQ:JAGX) develops gastrointestinal drugs, including Mytesi for diarrhea in people with HIV. Under a privately negotiated exchange, it issued 481,584 shares to Streeterville Capital, LLC in return for a USD 3,400,000 cut in the balance of a secured note, while the …
Liquidia Corporation (NASDAQ:LQDA) sells Yutrepia, an inhaled dry-powder form of treprostinil approved in 2025 for pulmonary arterial hypertension and for pulmonary hypertension associated with interstitial lung disease, known as PH-ILD. The '327 patent covers methods of treating PH-ILD with inhaled treprostinil and certain dry-powder …
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) develops molecular glue degraders, small molecules that make cells destroy a chosen protein. MRT-8102 targets NEK7, a protein required for the NLRP3 inflammasome, an immune complex that drives release of IL-1 and IL-6 and, in turn, C-reactive protein. High-sensitivity …
Apimeds Pharmaceuticals US, Inc. (NYSEAMERICAN:APUS) listed through an initial public offering in May 2025 to develop biologic, non-opioid treatments for pain. In December 2025 it merged with MindWave Innovations, which offers corporate bitcoin treasury wallets, AI-enhancedYieldand a validator ecosystem built around the NILA token. …
Please wait processing your request...